Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

[1]  T. Jacks,et al.  Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS: gelsolin complex , 2007, Oncogene.

[2]  A. Iafrate,et al.  Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling , 2007, Proceedings of the National Academy of Sciences.

[3]  J. Gordon,et al.  Inducible Gene Knockouts in the Small Intestinal and Colonic Epithelium* , 1999, The Journal of Biological Chemistry.

[4]  R. Kucherlapati,et al.  K-ras is an essential gene in the mouse with partial functional overlap with N-ras. , 1997, Genes & development.

[5]  Channing J Der,et al.  Increasing complexity of Ras signaling , 1998, Oncogene.

[6]  Manuel Serrano,et al.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.

[7]  R. DePinho,et al.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.

[8]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[9]  Daniel Metzger,et al.  Tissue‐specific and inducible Cre‐mediated recombination in the gut epithelium , 2004, Genesis.

[10]  R. Ren,et al.  Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. , 2007, Cancer research.

[11]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[12]  F. Cominelli,et al.  Mouse models for the study of Crohn's disease. , 2003, Trends in molecular medicine.

[13]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[14]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[15]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Julie A. Wilkins,et al.  Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo , 2006, Proceedings of the National Academy of Sciences.

[17]  Hideyuki Okano,et al.  Identification of a putative intestinal stem cell and early lineage marker; musashi-1. , 2003, Differentiation; research in biological diversity.

[18]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[19]  M. Malumbres,et al.  Targeted Genomic Disruption of H-ras and N-ras, Individually or in Combination, Reveals the Dispensability of Both Loci for Mouse Growth and Development , 2001, Molecular and Cellular Biology.

[20]  Carmine Vecchione,et al.  Replacement of K‐Ras with H‐Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice , 2005, EMBO reports.

[21]  Thierry Soussi,et al.  Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. , 2002, Gastroenterology.

[22]  R. Klemke,et al.  Four Human Ras Homologs Differ in Their Abilities to Activate Raf-1, Induce Transformation, and Stimulate Cell Motility* , 1999, The Journal of Biological Chemistry.

[23]  J. Pessin,et al.  Insulin stimulation of a MEK-dependent but ERK-independent SOS protein kinase , 1996, Molecular and cellular biology.

[24]  M. Giovannini,et al.  Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers , 2004, Laboratory Investigation.

[25]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[26]  Leroy Hood,et al.  PTEN-deficient intestinal stem cells initiate intestinal polyposis , 2007, Nature Genetics.

[27]  S. Shirasawa,et al.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.

[28]  J. Pouysségur,et al.  Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. , 2003, Biochemical pharmacology.

[29]  T. Jacks,et al.  The Related Retinoblastoma (pRb) and p130 Proteins Cooperate to Regulate Homeostasis in the Intestinal Epithelium* , 2006, Journal of Biological Chemistry.

[30]  S. Söldner-Rembold,et al.  The first 30 years , 1983 .

[31]  C. Der,et al.  Cellular N-Ras Promotes Cell Survival by Downregulation of Jun N-Terminal Protein Kinase and p38 , 2002, Molecular and Cellular Biology.

[32]  R. Coffey,et al.  Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium , 2007, Journal of cellular physiology.

[33]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[34]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[35]  Christopher S Potten,et al.  The intestinal epithelial stem cell. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[36]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[37]  G. Tzivion,et al.  Raf kinases: function, regulation and role in human cancer. , 2007, Biochimica et biophysica acta.

[38]  P. Sharp,et al.  Cre-lox-regulated conditional RNA interference from transgenes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Gordon,et al.  Genetic mosaic analysis based on Cre recombinase and navigated laser capture microdissection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.